Grave’s Disease Market (2021 to 2027) – Growth, Trends, COVID-19 Impact and Forecasts

Grave’s Disease Market was valued at US$ 360.7 Mn. in 2021. The Global Grave’s Disease Market size is estimated to grow at a CAGR of 4.1 % over the forecast period.

Grave’s Disease Market Overview:

The report explores the Grave’s Disease Market and its segments (Treatment, Diagnosis, and Region). Data has been provided by market participants and regions (North America, Asia Pacific, Europe, Middle East & Africa, and South America). This market report provides a thorough analysis of the rapid advances that are currently taking place across all industry sectors. Facts and figures, illustrations, and presentations are used to provide key data analysis for the historical period from 2017 to 2020. The report investigates the Grave’s Disease Market's drivers, limitations, prospects, and barriers. This MMR report includes investor recommendations based on a thorough examination of the Grave’s Disease Market's contemporary competitive scenario. Grave’s Disease Market To know about the Research Methodology :- Request Free Sample Report 2021 is considered as a base year to forecast the market from 2022 to 2027. 2021’s market size is estimated on real numbers and outputs of the key players and major players across the globe. The past five years' trends are considered while forecasting the market through 2027. 2020 is a year of exception and analysis, especially with the impact of lockdown by region.

Grave’s Disease Market Dynamics:

Grave’s disease is an autoimmune disorder that can cause hyperthyroidism or overactive thyroid. The major factor driving the growth of the market is the growing prevalence of autoimmune disorders such as thyroid, which has created the demand for its treatment. The growing patient population and the demand for quality healthcare are other factors boosting the growth of the market. Individuals who are suffering from diabetes are likely to increase the prevalence of grave disease and are expected to create opportunities for increased demand for advanced treatment options, which in turn will boost the grave disease market. The competition could lead to falling in the prices of the products because the intense competition from local manufacturers that offer products at low cost in the market is expected to hamper the growth of the market. The manufacturers are expected to provide up-to-date solutions to the customer with continuous technological development in the autoimmune disease diagnostic market. These are some of the major challenges faced by the grave disease market.

Grave’s Disease Market Trends:

The rapid expansion of knowledge on pathogeny, diagnosis, and treatment of Grave’s disease over the last decade has prompted discussion in endocrinological societies’ scientific sessions regarding the dissemination of information and awareness of new diagnostic and therapeutic aspects of the disease. The advancement of new technologies that have allowed ultrasound to become more widely accepted for soft tissue diagnosis is anticipated to offer lucrative opportunities for market growth. The increasing investment in research and development is expected to create opportunities for the market during the forecast period. COVID-19 Impact: The pandemic has affected both pulmonary and systemic inflammation, potentially determining multi-organ dysfunction. The virus has been reported to be a trigger for new or recurrent autoimmune thyroid disease. The virus is believed to trigger an immunological response causing reactivation of Grave’s disease. Thyroid autopsies in patients who were demised from COVID-19 infection do not indicate the presence of viral particles in the thyroid gland, the suggestive of an indirect, immune-mediated mechanism associated with destructive changes and cellular apoptosis.

Grave’s Disease Market Segment Analysis:

Based on Treatment, the Grave’s Disease Market is segmented into Anti-Thyroid Medication, Radioactive Iodine Therapy, and Surgery. The anti-thyroid segment holds the largest market share of more than 50% in 2021 and is expected to grow with the highest CAGR during the forecast period. It is used to prevent the thyroid from producing excess amounts of hormones. Grave’s Disease Market Based on Diagnosis, the Grave’s Disease Market is segmented into Ultrasound, Imaging tests, Radioactive Iodine Uptake, and Blood sample. The radioactive iodine uptake holds the largest segment and will remain the same during the forecast period. It slowly destroys the cells of the thyroid gland that produce thyroid hormone, and this therapy does not affect other body tissue. It is not used for women who are pregnant or breastfeeding because it can harm the fetus’s thyroid.

Grave’s Disease Market Regional Insights:

The North American region held the largest market share accounting for 36.9% in 2021. The rise in awareness about hyperthyroidism and increasing health investment will drive the growth of the market in this region. The Asia Pacific region is expected to witness significant growth at a CAGR of 8.42% through the forecast period. The increasing awareness and technological advancement in diagnostic techniques are likely to fuel the growth of the market in this region. The market for graves’ diseases is predicted to increase rapidly in the Asia-Pacific region. The growing prevalence of autoimmune disorders, as well as increased public awareness about the treatment of Graves' disease, are driving the regional market forward. Other factors driving market growth in the Asia-Pacific region include advancements in treatment technology, improved healthcare infrastructure, and increased public health programs. In addition, the rising prevalence of diabetes in the area, particularly in China, is one of the primary factors driving market growth. Due to the significant number of low- and middle-income persons in Asia-Pacific, people choose to use cost-effective treatment options like anti-thyroid drugs. The objective of the report is to present a comprehensive analysis of the global Grave’s Disease Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear, futuristic view of the industry to the decision-makers. The reports also help in understanding the Grave’s Disease Market dynamic and structure by analyzing the market segments and projecting the Grave’s Disease Market size. Clear representation of competitive analysis of key players by Design, price, financial position, product portfolio, growth strategies, and regional presence in the Grave’s Disease Market make the report investor’s guide.

Grave’s Disease Market Scope: Inquiry Before Buying

Grave’s Disease Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US$ 360.7 Mn.
Forecast Period 2022 to 2027 CAGR: 4.1% Market Size in 2027: US$ 459.3 Mn.
Segments Covered: by Treatment • Anti-Thyroid Medication • Radioactive Iodine Therapy • Surgery
by Diagnosis • Ultrasound • Imaging tests • Radioactive Iodine Uptake • Blood sample

Grave’s Disease Market by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Grave’s Disease Market Key Players:

Abbott Laboratories • GlaxoSmithKline plc • Merck & Co • Pfizer, Inc • RLC LABS • AbbVie, Inc • Mylan N.V • Allergan, plc • Novartis AG • Apitope • Amgen INC. • Sun Pharmaceuticals Industries LTD • Immunovant Inc Frequently Asked Questions: 1] What segments are covered in the Global Grave’s Disease Market report? Ans. The segments covered in the Grave’s Disease Market report are based on Treatment, Diagnosis, and Geography. 2] Which region is expected to hold the highest share in the Global Grave’s Disease Market? Ans. The North American region is expected to hold the highest share in the Grave’s Disease Market. 3] What is the market size of the Global Grave’s Disease Market by 2027? Ans. The market size of the Grave’s Disease Market by 2027 is expected to reach US$ 459.3 Mn. 4] What is the forecast period for the Global Grave’s Disease Market? Ans. The forecast period for the Grave’s Disease Market is 2021-2027. 5] What was the market size of the Global Grave’s Disease Market in 2020? Ans. The market size of the Grave’s Disease Market in 2020 was valued at US$ 360.7 Mn.
1. Global Grave’s Disease Market Size: Research Methodology 2. Global Grave’s Disease Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Grave’s Disease Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Grave’s Disease Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • The Asia Pacific • The Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Grave’s Disease Market Size Segmentation 4.1. Global Grave’s Disease Market Size, by Treatment (2021-2027) • Anti-Thyroid Medication • Radioactive Iodine Therapy • Surgery 4.2. Global Grave’s Disease Market Size, by Diagnosis (2021-2027) • Ultrasound • Imaging tests • Radioactive Iodine Uptake • Blood sample 5. North America Grave’s Disease Market (2021-2027) 5.1. North America Grave’s Disease Market Size, by Treatment (2021-2027) • Anti-Thyroid Medication • Radioactive Iodine Therapy • Surgery 5.2. North America Grave’s Disease Market Size by Diagnosis (2021-2027) • Ultrasound • Imaging tests • Radioactive Iodine Uptake • Blood sample 5.3. North America Grave’s Disease Market, by Country (2021-2027) • The United States • Canada • Mexico 6. European Grave’s Disease Market (2021-2027) 6.1. European Grave’s Disease Market, by Treatment (2021-2027) 6.2. European Grave’s Disease Market, by Diagnosis (2021-2027) 6.3. European Grave’s Disease Market, by Country (2021-2027) • The UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Grave’s Disease Market (2021-2027) 7.1. Asia Pacific Grave’s Disease Market, by Treatment (2021-2027) 7.2. Asia Pacific Grave’s Disease Market, by Diagnosis (2021-2027) 7.3. Asia Pacific Grave’s Disease Market, by Country (2021-2027) • China • India • Japan • South Korea • Australia • ASIANAN • Rest Of APAC 8. The Middle East and Africa Grave’s Disease Market (2021-2027) 8.1. The Middle East and Africa Grave’s Disease Market, by Treatment (2021-2027) 8.2. The Middle East and Africa Grave’s Disease Market, by Diagnosis (2021-2027) 8.3. Middle East and Africa Grave’s Disease Market, by Country (2021-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Grave’s Disease Market (2021-2027) 9.1. South America Grave’s Disease Market, by Treatment (2021-2027) 9.2. South America Grave’s Disease Market, by Diagnosis (2021-2027) 9.3. South America Grave’s Disease Market, by Country (2021-2027) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Company Name 1 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. GlaxoSmithKline plc 10.3. Merck & Co 10.4. Pfizer, Inc 10.5. RLC LABS 10.6. AbbVie, Inc 10.7. Mylan N.V 10.8. Allergan, plc 10.9. Novartis AG 10.10. Apitope 10.11. Amgen INC. 10.12. Sun Pharmaceuticals Industries LTD 10.13. Immunovant Inc

About This Report

Report ID 148495
Category Healthcare
Published Date May 2022
Updated Date
Contact Us